Calibrating Effects of a Novel Supplement Strategy on Vascular Measures of Aging
Key claim: Commercial combination longevity supplements frequently include compounds like glycine at doses far too low to reproduce the vascular health benefits observed in clinical studies.
Abstract
The supplement industry exists in its present vocal form because most people don’t care about effect size at all. Or accuracy. Or truth. They hear that something has an effect, and run out to buy it. The industry marketing is tuned to take advantage of this aspect of human nature. But what are the expected effect sizes for the better end of supplement strategies? This study reports on the effects of a combination supplement that rolls in some of the more interesting compounds assessed in recent years, including glycine - though of course at much lower doses than those used in the small GlyNAC study that showed quite surprisingly large benefits in old patients. Since no-one cares about effect size, why go to the trouble […]
Why this matters
Commercial combination longevity supplements frequently include compounds like glycine at doses far too low to reproduce the vascular health benefits observed in clinical studies.